



RECEIVED

SEP 11 2002

TECH CENTER 1600/2900

EXHIBIT B
PENDING CLAIMS

U.S. Patent Application Serial No. 09/750,972
(Attorney Docket 8449-134)
(as amended under 37 C.F.R. §1.111)

75. (amended) A method for treating or preventing an autoimmune disorder, proliferative disorder, or infectious disease comprising administering to a mammal an anti-CD91 antibody that binds alpha (2) macroglobulin receptor in an amount effective to treat or prevent the autoimmune disorder, proliferative disorder, or infectious disease in the mammal.

97. (amended) The method of claim 75, wherein the antibody modulates the interaction of the alpha (2) macroglobulin receptor with a heat shock protein.

99. (amended) The method of claim 97, wherein the heat shock protein is gp96.

100. (amended) The method of claim 97, wherein the heat shock protein is Hsp70.

101. (amended) The method of claim 97, wherein the heat shock protein is Hsp90.

104. (amended) The method of claim 75, wherein the method is a method for treating or preventing cancer.

105. (amended) The method of claim 104, wherein the anti-CD91 antibody modulates the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin receptor ligand, in an amount effective to treat or prevent cancer in the mammal.

106. The method of claim 104 or 105, wherein the cancer is selected from the group consisting of: human sarcomas or carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,

papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemias, polycythemia vera, lymphoma, multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease.

107. (amended) The method of claim 75, wherein the method is a method for treating or preventing an infectious disease.

108. (amended) The method of claim 107, wherein the anti-CD91 antibody modulates the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin receptor ligand.

109. The method of claim 107 or 108, wherein the infectious disease is caused by a infectious agent selected from the group consisting of: hepatitis type B virus, adeno-associated virus, cytomegalovirus, papilloma virus, polyoma viruses, SV40, adenoviruses, herpes simplex type I, herpes simplex type II, Epstein-Barr virus, poxviruses, variola vaccinia virus, RNA viruses, human immunodeficiency virus type I, human immunodeficiency virus type II, human T-cell lymphotropic virus type I, human T-cell lymphotropic virus type II, influenza virus, measles virus, rabies virus, Sendai virus, poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, rubella virus, Semliki forest virus, arboviruses, hepatitis type A virus, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Salmonella typhi*, *Treponema pallidum*, *Treponema pertenue*, *Treponema caratenum*, *Borrelia vincentii*, *Borrelia burgdorferi*,

Leptospira icterohemorrhagiae, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma spp.*, *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia spp.*, *Helicobacter pylori*, *Entamoeba histolytica*, *Trichomonas tenax*, *Trichomonas hominis*, *Trichomonas vaginalis*, *Trypanosoma gambiense*, *Trypanosoma rhodesiense*, *Trypanosoma cruzi*, *Leishmania donovani*, *Leishmania tropica*, *Leishmania braziliensis*, *Pneumocystis pneumonia*, *Plasmodium vivax*, *Plasmodium falciparum*, and *Plasmodium malaria*.

110. (amended) The method of claim 75, wherein the method is a method for treating or preventing an autoimmune disorder.

111. (amended) The method of claim 110, wherein the anti-CD91 antibody modulates the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin receptor ligand.

112. The method of claim 110 or 111, wherein the autoimmune disorder is selected from the group consisting of: insulin dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, pernicious anemia, autoimmune thyroiditis, idiopathic Addison's disease, vitiligo, gluten-sensitive enteropathy, Graves' disease, myasthenia gravis, autoimmune neutropenia, idiopathic thrombocytopenia purpura, rheumatoid arthritis, cirrhosis, pemphigus vulgaris, autoimmune infertility, Goodpasture's disease, bullous pemphigoid, discoid lupus, ulcerative colitis, and dense deposit disease.

121. (amended) The method of claim 75, 97, 104, 105, 107, 108, 110 or 111 wherein the anti-CD91 antibody is an agonist of the alpha (2) macroglobulin receptor.

122. (amended) The method of claim 75, 97, 104, 105, 107, 108, 110 or 111 wherein the anti-CD91 antibody is an antagonist of the alpha (2) macroglobulin receptor.

129. (new) The method of any one of claims 75, 97, 104, 105, 107, 108, 110 or 111 wherein the mammal is a human.

130. (new) The method of claim 108 or 111, wherein the alpha (2) macroglobulin receptor ligand is a heat shock protein.

131. (new) The method of claim 130, wherein the heat shock protein is hsp70, hsp90, or gp96.

132. (new) The method of any one of claims 75, 97, 104, 105, 107, 108, 110 or 111, wherein the antibody is purified.